Journal profile · Pharmacology & Pharmacy
Pharmacological Research
ISSN 1043-6618 · eISSN 1096-1186 · Academic Press Inc. · ENGLAND · Monthly · Founded 1989
Pharmacological Research: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 11.72; fully open access; APC about USD 4,130; median 79 days to acceptance (158 articles, last 24 months); community-reported acceptance: fairly easy; 493 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmacological Research is published by Academic Press Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Neuroscience and Neuropharmacology Research, Receptor Mechanisms and Signaling and Neuropeptides and Animal Physiology, together about 25.8% of its articles. Its main subfields are Cellular and Molecular Neuroscience. (generated from OpenAlex topic counts and CAS ranking data)
Bridging across disciplinesAn IUPHAR-affiliated journal, International Union of Basic and Clinical PharmacologyPharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. We provide a venue through which specialists across disciplines can rapidly exchange information in health sciences that pertains to modern pharmacological topics. The journal publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.Invited and unsolicited review articles are welcome.Journal SectionsSpecific sections are dedicated to:The cardiovascular system:CV disease therapy;Signal transduction and receptor pharmacology in the CV system;Target organs;Clinical trials.Neuroscience, including psychopharmacology, and neuroendocrinology:Understanding of the central nervous system in physiological and pathological conditions;Neuropharmacological and molecular mechanisms of learning and memory;Therapeutic and diagnostic challenges for mental illness and neurodegerative diseases;System biology.Oncology:Targeted cancer therapy;Precision medicine and personalized therapy;Signal transduction studies, as related to drug action;Clinical trials.Immunology (clinical and basic):Immune and inflammatory mechanisms including target identification;Immunotherapy and immunotoxicology;Immunopathology;Vaccines and adjuvants;Treatment of infectious diseases.Redox regulators and biological gases in pathophysiology:Oxidative and nitrative stress and cell dysfunction;Redox regulation of signal transduction in various diseases;Pathophysiological roles of NO, CO and H2S;Interaction between oxidants and gaseous mediators in health and disease;Pharmacological modulators of oxidants, free radicals and gaseous transmitters.Renal Pathophysiology and Pharmacology:Acute and chronic kidney injury disease;Metabolic alkalosis and metabolic acidosis in renal disease;Renal excretion in electrolyte disorders;Diabetes insipidus, Diabetic nephropathy;Pathogenesis of glomerular disease;End stage renal disease;Prevention and treatment of nephrotic diseases.Pregnancy Related Pharmacology and Perinatal Therapeutics:Drug effects on the mother and foetus before and after birth;Placental barrier and its relationship with drugs (transportation metabolism and so on);Molecular signalling in placenta and identification of mechanisms beyond drug action in pregnancy;Adverse effects of drugs drug/combination in placenta;Drug repurposing/reprogramming for placenta-related disorders;Regulatory aspects beyond clinical research in pregnant mothers;Placenta remodelling in disease;In vivo models of the diseased placenta;The microbioma;Effects of the environment on pregnancy;Preventive vs therapeutic use of drugs.Pharmacogenomics, Pharmacogenetics and Precision Medicine:We are especially interested in GWAS studies and studies reporting pharmacogenetic data that are relevant in terms of safety and efficacy of drugs. They must provide insight into novel genomic or therapeutic associations that can help guide therapy selection or suggest new indications for established drugs. Studies can also provide details of exceptional responses in limited numbers of patients.We also publish n=1 studies of exceptional responses, provided they are backed up by compelling genomic or experimental data.Studies must include full clinical description of the case, along with details of the response and supporting molecular information. The molecular information should support the clinical observations and offer a definitive pharmacogenomic insight. Standard clinical sequencing assays (Foundation ONE, Genoptix etc) are only appropriate when the therapeutic or phenotypic response is novel. Ideally, the observational patient studies should be supporte
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Emilio ClementiPublisher website
Editorial board by country: 50 in mainland China (about 29%); most named Mainland China 50, United States 35, Italy 27, Macau, China 9, France 6 (171 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neuroscience and Neuropharmacology ResearchNeuroscience10.1%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology9.5%
- Neuropeptides and Animal PhysiologyNeuroscience6.3%
- Nitric Oxide and Endothelin EffectsMedicine6.1%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience4.6%
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology4.5%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance3.8%
- Human auditory perception and evaluationEngineering3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 11.72LetPub ·
- Impact factor (publisher)
- 12.2Publisher website ·
- CiteScore 2026-06
- 19.1LetPub ·
- CiteScore (publisher)
- 19.1Publisher website ·
- SJR 2026-06
- 2.91LetPub ·
- SNIP 2026-06
- 2.16LetPub ·
- h-index
- 118LetPub ·
- h-index
- 223OpenAlex ·
- i10-index
- 6,208OpenAlex ·
- 2-year mean citedness
- 11.05OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 421LetPub ·
Articles by year OpenAlex count · 12,338 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 399 | 399 | 360 |
| 2025 | 493 | 493 | 4,425 |
| 2024 | 497 | 497 | 10,557 |
| 2023 | 384 | 384 | 11,428 |
| 2022 | 498 | 219 | 20,991 |
| 2021 | 558 | 149 | 29,320 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
79 daysMedian, submission to acceptance · P25–P75 63 days – 102 days
- Acceptance to online
- median 2 days (158 articles)
- Submission to online
- median 82 days
- Sample
- 158 articles with submission and acceptance dates (1,031 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- First decision after review
- 31 daysPublisher website ·
- Submission to acceptance
- 73 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,130 / EUR 3,860 / GBP 3,310 / JPY 512,240 | — | — | |
| LetPub | USD 4,510 | Yes | — | |
| Publisher website | USD 4,510 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers6, by deadline
- Pharmacological Targeting of Tauopathies: Novel Strategies and Therapeutic ChallengesDeadline
- Stem Cells, Exosomes, and Neurological Diseases: Novel Pharmacological Mechanisms and Translational TherapeuticsDeadline
- Targeting DNA Repair and Immune Modulation in Cancer TherapyDeadline
- Advanced Human Models for Drug Discovery and Immunopharmacology: Organoids, Organ-on-Chip, and BeyondDeadline
- Artificial Intelligence and Computational Approaches in Precision and Personalized Phytomedicine towards Improved Drug EfficacyDeadline
- AI-Driven Spatial Niches of Cancer Therapeutic Resistance: From Multi-Omics Discovery to Pharmacological TargetingDeadline
What to prepare3 items from the author guidelines
- Abstract
- ≤ 250 words
- Reference style
- Numbered, in order of citation
- Not considered
- case reports
Article types accepted13
- case reportOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- letters to the editorOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- meta-analysisOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- opinionOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- opinion articles and perspectivesOpinion articles and Perspectives. These articles provide expert views on future research and clinical trends in specific fields. These articles are solicited b…Length not stated
- original articleOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- original articlesOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- perspectiveOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- regular paperOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- research paperOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- review articleOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
- review articles and meta-analysesReview articles and meta-analyses. Review articles and meta-analyses are welcome but should be topical and not just an overview of the literature.Length not stated
- short communicationOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
single anonymized review Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Academic Press Inc.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1989
- ISSN
- 1043-6618
- Electronic ISSN
- 1096-1186
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Pharmacological Research
What CAS zone is Pharmacological Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacological Research is in Zone 2 of Medicine, and in Zone 1 of the minor category Pharmacology & Pharmacy; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacological Research?
The latest impact factor listed by LetPub is 11.72; CiteScore 19.1, h-index 223.
How long does peer review take at Pharmacological Research?
Based on the dates recorded on 158 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 79 days (interquartile range 63–102 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Pharmacological Research?
According to the journal's author guidelines: Abstract: ≤ 250 words; Reference style: Numbered, in order of citation. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Pharmacological Research based?
Of the 171 board members whose country the journal's board page names, 50 (about 29%) are in mainland China; the countries named most often are Mainland China (50), United States (35) and Italy (27). Counted from the institutions listed on the board page; for reference only.
Which databases index Pharmacological Research?
According to LetPub and DOAJ records, Pharmacological Research is indexed in SCIE, Scopus and DOAJ.
Is Pharmacological Research open access, and what is the APC?
Pharmacological Research is a fully open-access journal. APC about USD 4,130.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .